Short Interest in Hypermarcas (OTCMKTS:HYPMY) Declines By 43.9%

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a significant decline in short interest in July. As of July 31st, there was short interest totaling 3,256 shares, a decline of 43.9% from the July 15th total of 5,807 shares. Based on an average daily trading volume, of 19,962 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HYPMY. Zacks Research raised shares of Hypermarcas to a “hold” rating in a research note on Wednesday, April 29th. Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research note on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, Hypermarcas currently has an average rating of “Buy”.

Hypermarcas Trading Down 4.3%

HYPMY traded down $0.18 during trading hours on Tuesday, hitting $3.96. The company’s stock had a trading volume of 1,947 shares, compared to its average volume of 21,895. The stock has a market cap of $2.79 billion, a price-to-earnings ratio of 7.92 and a beta of 0.70. The business’s 50-day moving average price is $4.09 and its 200-day moving average price is $4.33. Hypermarcas has a 12 month low of $3.71 and a 12 month high of $5.50.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 14.63%. On average, analysts forecast that Hypermarcas will post 0.53 earnings per share for the current year.

Hypermarcas Company Profile

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.